TRLVHealthcare · Drug Manufacturers - Specialty & GenericThe 7 Wall Street analysts covering Trulieve Cannabis Corp. hold a median 12-month price target of $19 — +90.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 13 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Trulieve Cannabis Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (38): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TRLV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +90.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | $15 |
| 20 July 2026 | Cantor Fitzgerald | Initiates | Overweight | $15 |
| 20 July 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TRLV appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Trulieve Cannabis Corp. returned +22.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 55% of US stocks
Cheaper than 36% of US stocks
Cheaper than 47% of US stocks
Higher than 15% of US stocks
Higher than 26% of US stocks
Higher than 73% of US stocks
Higher than 69% of US stocks
Higher than 11% of US stocks
Higher than 22% of US stocks
Higher than 67% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Trulieve Cannabis Corp. has a market value of $1.9B and an enterprise value of $2.2B.
Revenue in the twelve months to 30 June 2026: $1.1B. The latest quarter shrank 10.3% year on year.
Net income over the same four quarters: −$476.2M, a −41.8% net margin.
Diluted earnings per share, trailing twelve months: $−2.45.
Free cash flow in the twelve months to 30 June 2026: $186.2M, after $50.2M of capital spending.
Trailing P/E: −16.6×; forward P/E: 18.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Trulieve Cannabis Corp. employs 5,000 people — $228K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Trulieve Cannabis Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlighted ICUI, NEOG and Trulieve Cannabis Corp. as medical product stocks positioned to benefit from industry tailwinds, saying they could be worth adding to investors’ portfolios.
Why it matters — The item places TRLV among three companies the source considers positioned to benefit from industry tailwinds.
Trulieve Cannabis Corp. announced it fully repaid approximately $65 million in mortgage notes secured by a cultivation site in Jefferson County, Florida. The repayment reduced outstanding debt to approximately $225 million.
Why it matters — The repayment and resulting debt reduction are relevant to watchers tracking Trulieve’s balance sheet.
Trulieve Cannabis Corp. said it will hold a conference call on November 5, 2026, at 8:30 a.m. Eastern Time, following the release of its third-quarter 2026 financial results.
Why it matters — TRLV watchers can note the scheduled call as an opportunity to hear the company discuss its third-quarter results.
The Motley Fool article highlights two cannabis companies as appealing options for aggressive investors in October, noting both reported higher second-quarter profits and stronger balance sheets than others in the sector. The excerpt does not identify whether Trulieve is among the two companies featured.
Why it matters — A Trulieve watcher would want to know whether the company is one of the two highlighted performers, as the article's criteria (higher Q2 profit and stronger balance sheet) could signal relative strength within the sector.
A Seeking Alpha author reiterates a Buy rating on the AdvisorShares Pure US Cannabis ETF despite the DEA pausing its cannabis rescheduling hearings, viewing the catalyst as delayed rather than canceled. The piece highlights Trulieve Cannabis Corp. as MSOS's largest holding, noting its Florida medical sales focus and normalized tax rates.
Why it matters — A TRLV watcher would care because the article singles out Trulieve as a standout holding within the cannabis ETF, reinforcing its positioning despite the rescheduling delay.
The 7 Wall Street analysts covering Trulieve Cannabis Corp. have a median 12-month price target of $19, with estimates ranging from $15 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Trulieve Cannabis Corp., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Trulieve Cannabis Corp. 86 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Oct 2026, Trulieve Cannabis Corp. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +90.6% from the last close, and Ticker Nerd's factor model ranks Trulieve Cannabis Corp. 86 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Trulieve Cannabis Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TRLV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $21 over the next 12 months.
Trulieve Cannabis Corp. returned +22.0% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Trulieve Cannabis Corp. is a vertically integrated cannabis company that cultivates, processes, manufactures, and retails cannabis products across the United States.
The most recent item we track (Zacks Investment Research, 9 Oct 2026): "3 Medical Product Stocks Positioned to Ride on the Industry Tailwinds". Zacks Investment Research highlighted ICUI, NEOG and Trulieve Cannabis Corp. as medical product stocks positioned to benefit from industry tailwinds, saying they could be worth adding to investors’ portfolios.
Trulieve Cannabis Corp. is a vertically integrated cannabis company that cultivates, processes, manufactures, and retails cannabis products across the United States. The company serves medical patients and adult-use consumers where permitted, using a network of branded dispensaries and home delivery services to distribute its products. Its portfolio includes flowers, edibles, vapes, concentrates, tinctures, topicals, and accessories sold under brands such as Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, Trekkers, and Roll One. Trulieve also operates cultivation and processing facilities that support product quality, supply consistency, and in-house production. The company plays a significant role in the U.S. cannabis market, with a strong emphasis on regulated retail, product development, and state-compliant operations.
CEO Ms. Kimberly Rivers J.D. · 5,000 employees · United States · https://www.trulieve.com
